Short answers from the drug label and studies
PT-141 Questions, With the Plain Answer First
You'll read the answer first, so you can judge it before checking the source.
How much did bremelanotide help women's desire?
Animal tests came first. Two Phase 3 trials then enrolled 1,267 women before menopause. This was a large, late test in people.
After 24 weeks, women reported slightly more desire and less distress [3]. Both chance tests were below .001. That means the differences were unlikely to be luck, not that the gains were large.
A review found only a modest gain over placebo, a dummy shot [10]. Some women may not have felt useful change. You can't treat an average as your result.
Does PT-141 lead to weight loss?
Weight loss isn't an approved use. Two Phase 1 studies followed women for 16 days [8]. This was early research in people.
The women ate about 400 calories per day less. They also lost a little more weight than women given placebo. The study amounts were far above the approved use.
That work didn't create a weight-loss approval [7]. You can't know why your hunger or weight changes without a proper health check.
Why study PT-141 with sildenafil, a PDE-5 pill?
Sildenafil is a common PDE-5 erection pill. It relaxes blood-vessel muscle [1]. That change lets blood enter the penis.
PT-141 works in the brain instead. It may affect desire rather than blood flow [1]. Your doctor would need to work out which problem, if either, affects you.
What is PT-141 in plain words?
PT-141 is the research name for bremelanotide. It's a small ring-shaped drug built from protein parts. It copies a hormone, a body chemical that carries messages [1].
A receptor on a brain cell receives that message [1]. Sexual desire may then change. FDA approval is limited to some women distressed by low desire [7].
What is the PT-141 peptide, a drug made from protein parts?
A peptide is a short chain of amino acids, the parts that build proteins. The PT-141 peptide has seven parts. They link into a ring [7].
Daltons are the units labs use to weigh tiny molecules. This ring weighs about 1,025 daltons. That figure won't predict your response.
The ring resists breakdown [7]. Bremelanotide then reaches brain cells linked with desire [1]. It can't promise you a gain.
What does the PT-141 peptide do in your body?
The drug attaches to receptors, the receiving points on brain cells [1]. In animals, it caused erections and made desire-linked nerve cells more active [1][3]. Women in human studies reported more desire and less distress.
Every woman in those studies was before menopause. The drug affected desire rather than blood flow [1]. Your own result could differ from the small average gain.
What PT-141 use has FDA approval?
FDA approval covers one use. It is for some women distressed by low desire [7]. Their desire must once have felt normal.
A woman can still have only one partner. The problem can't be limited to that partner or one kind of touch. Doctors call that broad pattern generalized low desire.
Men, later life, weight loss, and performance aren't approved uses [7]. This page can't give you medical care. Ask your doctor what the label means for you.
Do PT-141 and bremelanotide name the same drug?
Yes. "PT-141" was the research name. "Bremelanotide" is the later drug name [7]. Still, a name printed on a vial proves little.
FDA-approved bremelanotide must pass drug checks. "PT-141" sold for research may not pass them. You can't assume what's inside or how pure it is [7].
What is bremelanotide meant to change?
Bremelanotide is the drug name for PT-141. It's a ring-shaped drug made with protein parts [1]. It copies a hormone, a body message received by some brain cells [1].
Those cells help shape sexual desire. In 2019, FDA approved one use. It applies only before menopause to certain women [7].
How does PT-141 affect your brain?
The drug attaches to receptors, the receiving points on brain cells [1][2]. Those cells help shape wanting and sexual drive. Contact with a receptor triggers the cell's message.
It doesn't work like an erection pill. It may change desire without raising blood flow [1]. Your blood vessels don't have to open wider.
Which brain cells receive PT-141?
Scientists call the main kind receptor 4 and the related kind receptor 3 [1]. A receptor is where a cell receives a hormone message. Both kinds are deep in the brain and help shape desire.
Another related receptor helps set skin color. The drug may affect that kind too. You may then see darker skin after repeat use [7].
Does PT-141 change desire or blood flow?
PT-141 begins in your brain [1]. It reaches cells that shape desire and arousal. In 2022, scans showed two brain areas working more closely during sexual pictures.
The women reported a rise in desire too. That rise lasted up to 24 hours [5]. A scan can't show whether the change felt useful.
The drug doesn't relax blood vessels like the PDE-5 pill sildenafil [1]. It may affect desire when blood flow isn't the problem. That's the main difference for you.
What is a receptor on a brain cell?
A receptor is a receiving point on a cell [1]. Five related kinds in your body take hormone messages. PT-141 attaches to some and tells the cell to respond.
Two kinds sit deep in your brain. They can affect sexual desire [1]. You don't need their lab names to grasp the point.
Does PT-141 raise your testosterone level?
No. PT-141 doesn't directly raise testosterone [7]. Testosterone is a hormone made by glands. The drug doesn't work through those glands.
Instead, desire-linked brain cells respond [1]. Your testosterone level and sexual desire aren't the same thing. You may see one change while the other doesn't.
How does PT-141 differ from sildenafil, a PDE-5 pill?
Sildenafil is a PDE-5 pill that relaxes blood-vessel muscle. That can bring more blood into the penis [1]. The change may help your erection.
PT-141 works through brain cells that shape desire. It doesn't directly move more blood. Your doctor would need to tell which problem affects you [1].
What PT-141 dosage does the label list?
The FDA label lists 1.75 mg under the skin. That amount covers one approved use in certain women. The limits are once per 24 hours and eight shots in a month [7].
Half the drug leaves the blood in about 2.7 hours [7]. That tells you about blood, not how long you'd feel a change. It can't choose an amount for your body.
Can a website choose your PT-141 amount?
No. A website can't examine your body or health. For one approved use, the label lists 1.75 mg under the skin [7]. That label fact isn't a choice made for you.
Firm time limits also appear on the label. Your doctor can weigh your health and other drugs. You'll need that personal check before any prescription.
How much PT-141 is in the approved shot?
The approved shot contains 1.75 mg. The label caps use at once per 24 hours. It also sets a limit of eight shots in a month [7].
Those are label facts only. They don't tell you what fits your body. You'll need your doctor for a prescription and care.
What PT-141 dosage is approved for women?
The approved amount is 1.75 mg under the skin [7]. The approval only reaches some women before menopause. No other amount for women has approval.
Before human studies, PT-141 made female rats seek mating more often [2]. A rat finding can't foretell your response. You can't let animal work settle your choice.
Does approved PT-141 need mixing?
No. FDA-approved bremelanotide comes as a ready-to-use shot [7]. It isn't a powder that you mix. Mixing questions often concern powder sold only for research.
That powder doesn't get the same drug checks. Mixing steps aren't given here [7]. You can't assume the powder is safe.
How does the label say PT-141 is given?
The approved drug is an under-skin shot. Its label says at least 45 minutes before sexual activity. It also sets daily and eight-per-month limits [7].
Those facts only describe the label. They aren't steps for your own use. You'll need your doctor to guide your care.
Which time limits appear on the PT-141 label?
The label caps use at once per 24 hours. A limit of eight shots per month also applies [7]. The main studies used that same limit.
The cap may reduce harm from repeat use [7]. A 52-week follow-up uncovered no added safety problem [4]. You still can't call frequent use risk-free.